Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
MPM BioImpact is a biotechnology investment firm founded in 1997 and based in Cambridge, Massachusetts. As part of MPM Capital, one of the oldest and largest dedicated life sciences venture capital firms, MPM BioImpact has over 30 years of experience in the industry. The firm manages over $3 billion in assets under management (AUM) and has a portfolio that includes over 100 companies. MPM BioImpact focuses on investing in companies that are developing innovative therapies aimed at improving patient outcomes across various stages of drug development.
Since its inception, MPM BioImpact has established itself as a significant player in the biotechnology sector. The firm has achieved notable milestones, including backing over 55 IPOs and 40 M&A exits. Its commitment to transformative therapies positions it as a key partner for startups in the healthcare space. MPM BioImpact's extensive experience and resources enable it to provide strategic guidance and support to its portfolio companies, enhancing their growth and development.
MPM BioImpact invests in both private and public companies involved in the drug development process, with a strong emphasis on transformative therapies for patients suffering from serious diseases. The firm employs a unique investment approach known as the BIOIMPACT FUND™, which targets companies that aim to enhance patient outcomes through innovative solutions. MPM BioImpact's investment strategy encompasses a wide range of stages, including pre-seed, seed, seed-plus, Series A, Series B, and Series C.
The firm primarily focuses on the biotech and healthcare sectors, seeking to partner with companies that are developing groundbreaking therapies. MPM BioImpact looks for founders who demonstrate a strong vision and commitment to improving patient care. The firm is open to various deal structures and often collaborates with other investors to maximize the potential for impactful innovations in drug development.
MPM BioImpact's portfolio includes a diverse range of companies that are making significant strides in biotechnology and healthcare. Notable portfolio companies include:
These companies exemplify MPM BioImpact's commitment to investing in innovative therapies that aim to improve patient outcomes. The firm has a track record of supporting companies through various stages of development, contributing to their growth and success in the market.
Ansbert Gadicke, M.D. - Chairman. Dr. Gadicke has extensive experience in biotechnology investments and has played a pivotal role in MPM BioImpact's strategic direction.
Joseph Bolen, Ph.D. - Chief Executive Officer. Dr. Bolen has a strong background in life sciences and has led numerous successful investments in the biotech sector.
Frank Neumann, M.D., Ph.D. - Chief Medical Officer. Dr. Neumann brings expertise in clinical development and regulatory affairs, guiding portfolio companies through the drug development process.
Matthew Roden, Ph.D. - Chief Executive Officer of Aktis Oncology. Dr. Roden has a proven track record in oncology and has been instrumental in advancing Aktis Oncology's innovative therapies.
Todd Foley - Chairman of Aktis Oncology. Mr. Foley has significant experience in the biotech industry and provides strategic oversight for Aktis Oncology.
Michael Ehlers, M.D. - Board Member of Reunion Neuroscience. Dr. Ehlers has a strong background in neuroscience and contributes valuable insights to the development of Reunion Neuroscience's portfolio.
To pitch MPM BioImpact, founders should visit their website at mpmcapital.com. It is recommended to include a comprehensive deck that outlines the business model, market opportunity, competitive landscape, and team qualifications. MPM BioImpact appreciates detailed information about the technology and its potential impact on patient care.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review of the pitch.
In recent months, MPM BioImpact has been actively engaged in the biotechnology space, with notable developments in its portfolio companies. For instance, Aktis Oncology received FDA designations for its innovative therapies, signaling progress in its drug development efforts.
Additionally, Reunion Neuroscience has made strides in developing next-generation psychedelic-inspired pharmaceutical compounds, attracting attention for its potential impact on mental health disorders. Furthermore, Orna Therapeutics was recently acquired by Lilly, marking a significant exit for MPM BioImpact and highlighting the firm's successful investment strategy.
What are MPM BioImpact's investment criteria?
MPM BioImpact focuses on biotechnology and healthcare companies that are developing transformative therapies. They invest across various stages, from pre-seed to Series C, and look for companies that demonstrate a strong potential for improving patient outcomes.
How can I apply or pitch to MPM BioImpact?
Founders can submit their pitches through MPM BioImpact's website at mpmcapital.com. It is advisable to include a detailed business plan and information about the team and technology.
What makes MPM BioImpact different from other venture capital firms?
MPM BioImpact's unique investment approach, known as the BIOIMPACT FUND™, emphasizes transformative therapies and patient outcomes. Their extensive experience in biotechnology investments allows them to provide valuable strategic guidance to portfolio companies.
What is the geographic scope of MPM BioImpact's investments?
MPM BioImpact primarily invests in companies based in the United States, focusing on the biotech and healthcare sectors.
What is MPM BioImpact's post-investment involvement like?
MPM BioImpact actively engages with its portfolio companies, providing strategic guidance and facilitating connections within the industry to enhance growth and development. They often participate in board meetings and support follow-on investments.
What is the typical check size for investments made by MPM BioImpact?
While specific check sizes are not disclosed, MPM BioImpact invests across a range of stages, indicating flexibility in their investment amounts based on the needs of the company.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.